AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee
AIVITA Biomedical Announces New Positive Phase 2 Glioblastoma Data at SITC Annual Meeting Podium Presentation
Brain Cancer Patient Survival, Immune and Tumor Data from AIVITA Biomedical’s Phase 2 Clinical Trial to be Presented at SITC Annual Meeting
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November
AIVITA Biomedical Announces Publication Detailing Immune Mechanisms Leading to Complete Remission of Measurable Metastatic Melanoma in Patient Treated with AIVITA Immunotherapy
Brain Cancer Patients Display Appropriate Immune Responses and Decreasing Tumor Biomarkers in AIVITA Biomedical’s Phase 2 Clinical Trial
